From Dealroom · · 30s
Ligand Completes $739M XOMA Deal
Ligand's royalty revenue jumps 51% after $739M acquisition of XOMA.
In brief
Ligand's royalty revenue jumps 51% after $739M acquisition of XOMA. Ligand Pharmaceuticals completed a $739 million deal with XOMA, boosting royalty revenue by 51% year over year to $70.3 million. Originally reported by Dealroom.
Deal Completion
Ligand Pharmaceuticals completed its $739 million acquisition of XOMA in July.
Royalty Revenue Growth
Third-quarter royalty revenue rose 51% year over year to $70.3 million.
Filspari Impact
Filspari generated $16.8 million in Q3 royalties, up 85% year over year.
The essence
Ligand Pharmaceuticals completed a $739 million deal with XOMA, boosting royalty revenue by 51% year over year to $70.3 million.
